ArticleFrontiers in pharmacology2025
The first step for understanding the molecular mechanism of the antifibrotic effect of inhaling 25(OH)-vitamin D3 and 1,25(OH)
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Therapeutic Efficacy of Inhaled Vitamin D3 Metabolites Initiated During the Acute Phase of Hypersensitivity Pneumonitis: An In Vivo Study.Molecules (Basel, Switzerland) · 2026Article
- Targeting the fibrosis-inflammation-oxidative stress axis: multifaceted mechanisms of salidroside in chronic organ fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
- Reconsidering Vitamin D Supplementation in Pulmonary Disease: The Case for Targeted Respiratory Delivery.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Vitamin D3-Deficient Diet Promotes Pulmonary Fibrosis Development in Murine Model of Hypersensitivity Pneumonitis.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary fibrosis occurs in several respiratory diseases, among which hypersensitivity pneumonitis (HP) is often ignored in designing therapeutic strategies. We strive to fill these knowledge gaps. Our earlier studies revealed antifibrotic potential of the inhalation of 1,25(OH)2-VD3 and 25(OH)-VD3 based on modulation of the immune response and deposition of extracellular matrix components, both of which are important components of epithelial-mesenchymal transition (EMT), which we focused on in this research. The study aimed to describe the direct impact of VD3-metabolites on EMT in the course of pulmonary fibrosis in HP to understand their therapeutic effect. Methods: The research was performed in the HP model, wherein pulmonary fibrosis is induced in mice by chronic exposure to antigens of Results and discussion: The studies revealed that VD3-deficiency triggers EMT, the signs of which were increased expression of EMT transcription factors (Snail1, Snail2, Zeb1, and Zeb2), inhibited expression of epithelial cell markers (E-cadherin and occludin), and altered expression of mesenchymal cell markers, including upregulated N-cadherin and vimentin. Pathological changes caused by VD3-deficiencies accelerated in response to SE-PA, the signs of which were: 1) upregulated expression of Snail1, Snail2, Zeb1, Zeb2, Acta2, Cdh2, Fn1, and Vim; 2) downregulated expression of Cdh1 and Ocln; 3) increased level of α-SMA, fibronectin, vimentin, and occludin; 4) decreased amount of N-cadherin; 5) increased deposition of fibers in lung tissue. All negative changes recorded on the transcriptome level in VD3-deficient mice with HP were effectively reduced by inhalations of 25(OH)-VD3 and 1,25,25(OH)2-VD3, suggesting that their antifibrotic effects are associated with EMT inhibition. Nevertheless, the beneficial impact of VD3-metabolites on the proteome level was associated with restoration of the balance in the expression of EMT molecules disturbed by cholecalciferol deficiency and SE-PA exposure; metabolites lowered the overexpressed amounts of fibronectin, vimentin, and occludin and simultaneously increased the expression of vitamin D3 metabolites downregulated N-cadherin and enhanced of vitamin D3 metabolite expression of E-cadherin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.